As an emerging kind of crystalline material, the metal-organic framework (MOF) has shown great promise in the biomedical domains such as drug storage and delivery. In this study, a new porous MOF, [[Dy 2 (H 2 O) 3 (SDBA) 3 ](DMA) 6 ] (1, H 2 SDBA � 4,4′-sulfonyldibenzoic acid, DMA � N,N-dimethylacetamide (C 4 H 9 NO)), with uncoordinated O donor sites has been fabricated using a bent polycarboxylic acid organic linker under the solvothermal condition. e structure of the obtained crystalline product has been fully determined by the X-ray single-crystal diffraction, TGA, elemental analysis, XRD, and the gas sorption measurement. Due to the suitable window size and polar atom functionalized 1D channels, the activated 1 (1a) compound was used for the anticancer drug 5-fluorouracil (5-Fu, C 4 H 3 FN 2 O 2 ) loading by a simple impregnation method. A moderate drug loading and pHdependent drug-release behavior could be observed for 1a. Furthermore, as indicated by the MTTassay, this drug/MOF composite shows low toxicity toward the human normal cells and demonstrates obvious anticancer activity against the human osteosarcoma cell line MG63.
Introduction
Being one of the most life-threatening diseases, cancer has caught the nerves of people all over the world because more and more people are suffering from cancer and die from it [1] . Currently, the most effective treatment method is still chemotherapy which relies on the anticancer drugs [2] . However, chemotherapy has always suffered some unbearable drawbacks such as nonspecific toxicity toward normal cells, poor solubility of the chemotherapy drug, and undesirable side effects [3] . In this case, great notice has been devoted to nanocarriers for anticancer drug delivery for cancer therapy, aiming at a targeted release of anticancer drugs while retarding the drug leaking into the healthy physiological environment [4] . e uncommon microenvironments at tumor sites such as low pH value, high glutathione (GSH) concentration, and different oxygen concentrations can be utilized to trigger drug release from the carriers.
As an emerging kind of crystalline material, the metalorganic framework (MOF) built via the assembly of organic ligands as bridges and metal ions as nodes has underwent a rapid development in the last two decades [5] [6] [7] . Recently, porous metal-organic frameworks have been proved to be very successful for drug delivery, possessing advantages such as high drug-loading capacity, suitable pore size, and strong drug-framework interaction [8, 9] . Furthermore, the toxicity of the MOFs toward the human normal cells can be tactfully averted by selecting biocompatible metals and organic ligands. In addition, the pore walls of MOFs could be conveniently gifted polar donor sites via selecting organic ligands with polar donor sites, which could form strong frameworkdrug interaction to result in the sustainable drug-release behavior. For instance, the anticancer drug-loaded ZIF-8 nanocarriers showing pH-sensitivite drug release have been achieved by Zhao and coworkers [10] ; Kotzabasaki et al. revealed that the hydroxyl groups in IRMOF-16 could lead to a much improved drug-loading capacity, which outperforms many other materials targeted for the gemcitabine loading [11] Figure 1) , with uncoordinated O donor sites has been fabricated using a bent polycarboxylic acid organic linker under the solvothermal condition. Although the H 2 SDBA ligand has been used in building the Dy-based coordination compounds in the previous literature, none of them are porous structures [12] .
e structure of the obtained crystalline product has been fully characterized by the X-ray single-crystal diffraction, elemental analysis, TGA, XRD, and the gas sorption measurement. Due to the suitable window size and polar atom functionalized 1D channels, the activated 1 (1a) was used for the anticancer drug 5-Fu loading by a simple impregnation method. A moderate drug-loading and sustainable drug-release behavior could be observed for 1a. Furthermore, as indicated by the MTT assay, this drug/MOF composite shows low toxicity toward the human normal cells and demonstrates obvious anticancer activity against the human osteosarcoma cell line MG63.
Experimental

Chemicals and Instruments.
All the chemicals are obtained from the regent companies and used as received. Elemental analyses (C, H, and N) were carried out with a Vario EL III Elemental analyzer. Powder X-ray diffraction (PXRD) curves were collected on a Difrac Plus XRD Commander diffractometer at room temperature. Measurements of the UV-Vis absorption spectra were carried out in a quartz cell using a Camspec M330 UV-Vis spectrometer. ermal gravity analysis (TGA) curves were collected using a NETZSCH STA449F3 thermal analyzer. e N 2 sorption data at 77 K were collected on the Autosorb 1 by Quantachrome. e HPLC analysis was conducted using the 1260 Agilent chromatographic system. 2 (H 2 O) 3 (SDBA) 3 ](DMA) 6 ]. In a 50 mL beaker, Dy(NO 3 )·6H 2 O (46 mg, 0.1 mmol), H 2 SDBA (31 mg, 0.1 mmol), DMA (6 mL), and H 2 O (1.5 mL) were added. After the addition of 0.2 mL HCl (2 M aq.), the mixture was stirred for 30 min in the air to make a clear solution, and then, the mixture was placed in a 20 mL vial and kept at 90°C for two days. Yellow sheet crystals of 1 were obtained by filtration, washed with water, and left in the air for one day to make them dry. e yield was 46% based on the H 2 
Preparation of [[Dy
Crystal Structure Determination.
e X-ray singlecrystal diffraction data of 1 were collected on the Oxford diffraction Xcalibur CCD diffractometer with Mo Kα radiation.
e structural model of 1 was solved by direct methods using the SHELXT program, and the obtained model was amended using the SHELXL program. All hydrogen atoms attached to oxygen and carbon were generated geometrically and all non-hydrogen atoms were refined anisotropically. For the disordered nature of the DMA molecules, they could not be figured out from the structural model, so their electrons were removed from the HKL file using the SQUEEZE manipulation in the software PLATON (the total unit cell includes six DMA molecules (48e * 6 � 288e), and the SQUEEZE result reveals that 596 electrons were removed from the unit cell). is discrepancy might be owing to the different measurement conditions for the single-crystal X-ray analysis (tested after being sealed in a capillary filled with DMA) and TGA (tested after being dried in the air)). e solvents in the chemical formula of 1 were determined from the TGA curve and elemental analysis results. Relevant data concerning the crystal data and refinement parameters have been provided in Table 1 .
5-Fu Loading and
Release. Twenty milligrams of activated 1 (1a) were suspended in 8 ml of 5-Fu solutions, and then, the mixture suspensions were stirred for 72 h at 37°C. Finally, 5-Fu-loaded 1a was obtained through centrifugation for 5 min, washed with MeOH, and dried at room temperature. 1a before and after the 5-Fu entrapping were characterized by PXRD. e concentration of 5-Fu in the supernatant was determined by the absorbance of 5-Fu at 265 nm with the help of a calibration curve. en, the drugloading efficiency was calculated. Drug encapsulation efficiency � (total amount − without loading amount)/total e 5-Fu release experiment was compacted in the dialysis bag. e 5-Fu-loaded crystals of 1 were soaked in the PBS solution at different pH values (7.4 and 5.6) at 37°C. In each interval, 0.2 mL of the solution was taken out and fresh PBS with equal amount was added. en, the 5-Fu content was probed using the HPLC analysis.
GCMC Simulation.
e adsorption process of the 5-fluorouracil (5-Fu) molecule to 1a was investigated using grand canonical Monte Carlo (GCMC) simulations at 300 K. Interactions of 5-Fu with the frameworks were described by a potential composed of van der Waals and Coulomb components. Van der Waals interactions were treated using the Lennard-Jones (LJ) potential and atomic parameters taken from the UFF force field. Coulomb interactions were calculated using atomic partial charges obtained via the charge equilibration (Q eq ) method proposed by Snurr and coworkers. Partial charges for 5-Fu molecules were calculated at the B3LYP level using the DMOL3 module. GCMC simulations were carried out with 1 × 10 7 equilibration steps and 2 × 10 7 production steps. e configuration-bias Monte Carlo method was used for trial MC moves involving insertion and deletion of 5-Fu molecules. All GCMC simulations were performed using the sorption module embedded in Material Studio 6.1.
In Vitro Toxicity
Tests. e cytotoxicity toward HASM (human aortic smooth muscle) cells and MG63 cells was determined using MTT assays. e cells were seeded in a 96-well microplate. After 24 h of cell attachment, the cells were treated and incubated with different concentrations of each complex for 48 h. en, 25 μl of MTT solution was added into each well. After the cells were incubated for another 4 hours, 150 μl of DMSO was added to each well to dissolve the MTT formazan crystals. At last, the absorbance of each well was monitored through a microplate reader.
Results and Discussion
Molecular Structure and Physical Characterization of 1.
Crystallographic analysis via the X-ray single-crystal diffraction reveals that compound 1 locates in the monoclinic crystal system and P2 1 /c space group and shows a threedimensional channel-type framework. e molecular unit is composed of two independent Dy(III) ions, three SDBA 2− ligands, and three coordinated water molecules. As plotted in Figure 2 are comparable to those observed in the Dy-based metalorganic frameworks. e Dy1, Dy2, and their symmetryrelated atoms are held together via the syn-bridging carboxylic groups along the a-axis to afford the 1D secondary building unit chains with the Dy1-Dy2 separation of 5.04Å. As for the SDBA 2− ligands, they exhibit three different coordination modes with the two carboxylic groups binding with one or two Dy 3+ ions forming paddle-wheel units (Figure 2(b) ). e SDB ligands are bent with the C-S-C bond angles ranging from 101.7 (2) to 103.6 (2)°, which connect with the 1D SUB channels to afford the three-dimensional framework with rhombus channels (Figure 2(c) ). e channels are filled with uncoordinated O donors site and water-occupied Dy(III) sites, which are potentially favorable for guests binding. e total effective solvent accessible volume is 2172Å 3 , corresponding to 37.3% of the cell volume. In the framework of 1, the three SDBA 2− ligands in the molecular unit could be judged as 3-,4-, and 5-connected nodes, and the two Dy(III) ions could be viewed as 5-and 6-connected nodes; so the whole framework of 1 can be abstracted as a 3-, 4-, 4-, 5-, and 6-connected topological network with the Schläfli symbol of {4.6.8}{4^2.6^3.8^5}{4^3.6^2.8}{4^3.6^3} {4^9.6^6}, which has not been included in the TOPOS database (Figure 2(d) ).
In order to determine the obtained 1 more fully in terms of phase purity and thermal stability, we carried out the PXRD measurements and TGA experiments. As shown in Figure 3(a) , the good match between the simulated and experimental PXRD patterns indicates the high phase purity of the as-synthesized 1. Considering the following drug delivery experiments, the stability of 1 in water has been checked by soaking the crystalline samples of 1 in water for one day, and then, the corresponding PXRD patterns were collected, which reveal that the water surroundings could not lead to the transformation of the framework of 1, confirming its good water stability. To probe the lattice solvents in the framework of 1, the TGA experiments were carried out (Figure 3(b) ). A weight loss of 32.3% was observed in the temperature range of 25 to 429°C, which can be attributed to the release of three coordinated water and six lattice DMA molecules. After reaching 429°C, a sharp weight loss could be observed for 1, which indicates the collapse of the framework. To establish the permanent porosity of the solvent-free samples of 1 (1a), the as-prepared crystalline samples of 1 were soaked in the anhydrous MeOH for three days to exchange with the lattice DMA molecules, and then activated at 60°C for 12 hours. e full activation of 1a has been confirmed via the TGA experiments, which reveals that no obvious weight loss could be found in the temperature range of 25 to 429°C. To determine the surface area of 1a, N 2 sorption isotherm was collected at 77 K. 1a shows a type-I sorption behavior with the maximum N 2 uptake capacity of 294 cm 3 /g, which indicates complex 1a is a microporous material (Figure 3(c) ). e Brunauer-Emmett-Teller (BET) surface area was calculated to be 1222 m 2 /g, indicating the space of 1a could house considerable amount of guest molecules. Furthermore, the hole diameter and distribution calculated from the 77 K N 2 sorption method reveals a hole size distribution around 0.95 nm, illuminating the potential of accepting guests in the pores (Figure 3(d) ).
Drug Delivery Experiment.
In light of its large BET surface area and suitable pore size, complex 1a has the potential for loading small guest molecules. In this work, 5-fluorouracil (5-Fu) with the molecular size of 5.3 × 5.0Å 2 was chosen as the guest molecules because it is a widely used drug molecule for the cancer treatment. e drug-loading experiments were carried out by impregnating of 1a (10 mg) in 5 mL MeOH solution containing 20 mg of 5-Fu with consciously stirring for two hours, and then, the 5-Fu concentration in the MeOH solution was detected via the UV-Vis spectroscopy. As shown in Figure 4(a) , there is an obvious decrease in the intensity of the UV-Vis spectrum at 254 nm, indicating that the 5-Fu molecules are absorbed into the pores of 1a (Figure 4(a) ). e 5-Fu storage capacity is 20.6 wt.% (this means every 100 g of 5-Fu/1a composite contains 20.6 g of 5-Fu) based on the UV-Vis spectrum result. Furthermore, the N 2 sorption experiment of the 5-Fuloaded 1a indicates that it could hardly adsorb any N 2 under the given conditions, revealing that the pore spaces of 1a are effectively occupied by the drug molecules. e drug sustained-release experiment was studied under different conditions (pH 7.4 at 37°C and pH 5.6 at 37°C), and the 5-Fu released concentration was determined by HPLC. As shown in Figure 4 (b), the amount of 5-Fu released from 5-Fu-loaded 1a is 50% in the first 40 h, and further increasing the time could not lead to more 5-Fu released from the carrier. e present result also indicates that the 5-Fu drug could not be completely released from the carrier under the present conditions. When the pH value of the PBS solution was adjusted to 5.6, it could be observed that the release rate is much faster with nearly 70% of 5-Fu molecules being released into the solution, indicating that the 5-Fu release is pH independent (Figure 4(b) ). e slightly large release rate might be due to the partly decomposition of the framework. To understand the interaction between the 5-Fu molecules and the framework, the GCMC simulation was carried out. As shown in Figure  4 (c), the simulated favorable binding site of 5-Fu at zero loading indicates that the one 5-Fu molecule prefers to locate in the channel center with short H-bond and Dy-O interactions could be observed (2.991Å and 2.915Å). Furthermore, besides the H-bond interactions, there also exists π-π interaction between the 5-Fu molecule and the benzene ring of the ligand with a distance of 3.370Å. All these interactions contribute to the strong binding energy of 5-Fu with the framework, resulting in the long-lasting drug release. Figure 4(d) shows the distribution of 5-Fu molecules in the framework of 1a at 37°C and 100 kPa, which reveals that each unit cell of 1 could house 11 5-Fu molecules, corresponding to 22.4 wt.%, which is near to the value calculated from the UV-Vis spectrum.
3.3. Anticancer Activity. As a drug delivery system, its cytotoxicity toward the human normal cells should be considered. With this in consideration, the cytotoxicity of the 5-Fu-loaded 1a and the 5-Fu were studied against the HASM (human aortic smooth muscle) cells via the standard MTT method. e HASM cells were incubated with 5-Fu-loaded 1a and 5-Fu with various concentrations, and the corresponding cell viabilities were recorded. As shown in Figure 5 (a), the cell viabilities are all above 92% under various concentrations of 5-Fu-loaded 1a, indicating that this drug-MOF composite has little toxicity toward the human normal cells. Furthermore, compared with the drug 5-Fu, the drug-MOF composite shows more cell viability, illuminating that the drug-MOF might possess less side effect compared with the pure drug. To probe the anticancer activity of the 5-Fu-loaded 1a, the in vitro antitumor activity was studied against the human osteosarcoma cell line MG63 under different concentrations for 24 h and 48 h, respectively. As shown in Figure 5(b) , the 5-Fu-loaded 1a exhibits potent cytotoxicities against the MG63 cells, with about 60% cancer cells killed at 24 h. Interestingly, further prolonging the experimental time could lead to more cell death, indicating the long-lasting drug release.
Conclusion
In summary, we have successfully prepared a novel porous MOF using a V-shaped polycarboxylic acid organic linker under the solvothermal condition. e as-prepared MOF is composed of 1D chain-like SBUs that were linked via the ligands to afford the 3D framework with 1D microporous channels running along the a-axis. Due to its suitable pore size and high density of O donor sites, it could behave as an effective carrier for the 5-Fu capture and release, and a moderate 5-Fu-loading capacity and pH-dependent drug release behavior could be observed. Furthermore, the MTT assay reveals the low cytotoxicity of the 5-Fu-loaded 1a and notable anticancer activity against the human osteosarcoma cell line MG63.
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